Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers(Rockefeller University), Leonard G. Presta, Jeffrey V. Ravetch(Rockefeller University)

Nature Medicine

April 1, 2000

Cited by 2,736

Abstract

Related Papers

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Paul Carter, Leonard G. Presta, C Gorman et al.|Proceedings of the National Academy of Sciences|1992|1.9k

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes et al.|Journal of Clinical Oncology|1998|1.1k

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

José Baselga, Larry Norton, Joan Albanell et al.|PubMed|1998|1k

FcR γ chain deletion results in pleiotrophic effector cell defects

Toshiyuki Takai, Min Li, Diana L. Sylvestre et al.|Cell|1994|968

Augmented humoral and anaphylactic responses in FcγRII-deficient mice

Toshiyuki Takai, Masao Ono, Masaki Hikida et al.|Nature|1996|824